OptiNose (OPTN) to Release Quarterly Earnings on Tuesday

OptiNose (NASDAQ:OPTN) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.74) per share and revenue of $17.70 million for the quarter.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.67. The business had revenue of $21.47 million for the quarter, compared to the consensus estimate of $21.02 million. On average, analysts expect OptiNose to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OptiNose Price Performance

Shares of NASDAQ:OPTN opened at $9.39 on Monday. The company’s 50-day moving average price is $8.39 and its two-hundred day moving average price is $7.47. The stock has a market capitalization of $95.09 million, a PE ratio of -2.24 and a beta of -0.88. OptiNose has a one year low of $4.82 and a one year high of $20.03.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on OPTN shares. Piper Sandler restated a “neutral” rating and set a $9.00 target price (down from $15.00) on shares of OptiNose in a report on Friday, March 21st. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 target price (down from $18.00) on shares of OptiNose in a report on Friday, March 21st. Finally, Lake Street Capital cut shares of OptiNose from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $17.00 to $9.00 in a research report on Thursday, March 20th.

Insider Activity at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares of the company’s stock, valued at $671,464.99. The trade was a 4.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 8,213 shares of company stock worth $43,643. Insiders own 2.30% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.